<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Helwick, Caroline</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Boden, William E.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">The COURAGE Trial: Optimal Medical Therapy Equivalent to PCI</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2007</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2007-05-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">21-22</style></pages><abstract><style  face="normal" font="default" size="100%">Percutaneous coronary intervention (PCI) is a widely used method of restoring normal blood flow to the myocardium and is lifesaving during acute coronary events. There are little long-term clinical outcome data, however, on the benefits of PCI in patients who have stable coronary artery disease. This article discusses the results of the Clinical Outcomes Utilizing Revascularization and Aggressive Guideline-Driven Drug Evaluation study [COURAGE; N Engl J Med 2007; 356:1503–1516].</style></abstract><number><style face="normal" font="default" size="100%">1</style></number><volume><style face="normal" font="default" size="100%">7</style></volume></record></records></xml>